Tardive dyskinesia (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Tardive dyskinesia" in English language version.

refsWebsite

Global rank English rank

52nih.gov

4^th place

36doi.org

2^nd place

12semanticscholar.org

11^th place

8^th place

10web.archive.org

1^st place

5worldcat.org

5^th place

2sciencedirect.com

149^th place

178^th place

2books.google.com

3^rd place

2archive.org

6^th place

2fda.gov

447^th place

338^th place

1rarediseases.org

5,181^st place

3,260^th place

1wiley.com

222^nd place

297^th place

1medscape.com

719^th place

636^th place

1nami.org

low place

1dukehealth.org

low place

1priory.com

low place

1springer.com

274^th place

309^th place

1psychiatryonline.org

4,032^nd place

6,573^rd place

archive.org

Glenmullen, Joseph (2001). Prozac Backlash: Overcoming the Dangers of Prozac, Zoloft, Paxil, and Other Antidepressants With Safe, Effective Alternatives. New York: Simon & Schuster. p. 38. ISBN 978-0-7432-0062-2.^{[unreliable medical source?]} ::referring to Glazer, William M.; Morgenstern, Hal; Doucette, John T. (1993). "Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications". Journal of Clinical Psychiatry. 54 (4): 133–139. PMID 8098030.
Whitaker, Robert (2002). Mad in America: Bad Science, Bad Medicine, and the Enduring Mistreatment of the Mentally Ill. Perseus. ISBN 978-0738203850.^{[page needed]}

books.google.com

Ross, Colin A; Read, John (2004). "Antipsychotic medication: myths and facts". In Read, John; Mosher, Loren R.; Bentall, Richard P. (eds.). Models of Madness: Psychological, Social and Biological Approaches to Schizophrenia. London: Brunner-Routledge. pp. 101–14. ISBN 978-1-58391-906-4.
Lerner, Vladimir (2011). "Antioxidants as a Treatment and Prevention of Tardive Dyskinesia". In Ritsner, Michael S. (ed.). Handbook of Schizophrenia Spectrum Disorders, Volume III. pp. 109–134. doi:10.1007/978-94-007-0834-1_6. ISBN 978-94-007-0833-4.

doi.org

Vijayakumar, D; Jankovic, J (May 2016). "Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia". Drugs. 76 (7): 779–787. doi:10.1007/s40265-016-0568-1. PMID 27091214. S2CID 13570794.
Carbon, M; Hsieh, CH; Kane, JM; Correll, CU (March 2017). "Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis". The Journal of Clinical Psychiatry. 78 (3): e264 – e278. doi:10.4088/jcp.16r10832. PMID 28146614. S2CID 3773500.
Gerlach, J.; Casey, D.E. (1988). "Tardive dyskinesia". Acta Psychiatrica Scandinavica. 77 (4): 369–378. doi:10.1111/j.1600-0447.1988.tb05138.x. ISSN 0001-690X. PMID 2898870.
Waln, Olga; Jankovic, Joseph (2013). "An Update on Tardive Dyskinesia: From Phenomenology to Treatment". Tremor and Other Hyperkinetic Movements. 3. doi:10.7916/D88P5Z71 (inactive 2024-11-01). PMC 3709416. PMID 23858394.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Waln, Olga; Jankovic, Joseph (2013-07-12). "An Update on Tardive Dyskinesia: From Phenomenology to Treatment". Tremor and Other Hyperkinetic Movements. 3: tre–03–161-4138-1. doi:10.7916/D88P5Z71 (inactive 2024-11-01). ISSN 2160-8288. PMC 3709416. PMID 23858394.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Yassa, R.; Lal, S. (1986). "Respiratory irregularity and tardive dyskinesia a prevalence study". Acta Psychiatrica Scandinavica. 73 (5): 506–510. doi:10.1111/j.1600-0447.1986.tb02717.x. PMID 2875609. S2CID 25313407.
Yassa, Ramzy; Jones, Barry D. (1985). "Complications of tardive dyskinesia: A review". Psychosomatics. 26 (4): 305–307, 310, 312–313. doi:10.1016/S0033-3182(85)72863-0. PMID 2859630.
Dean, C. E.; Thuras, P. D. (2009). "Mortality and tardive dyskinesia: Long-term study using the US National Death Index". The British Journal of Psychiatry. 194 (4): 360–364. doi:10.1192/bjp.bp.108.049395. PMID 19336789.
Cho, Chul-Hyun; Lee, Heon-Jeong (2013-10-01). "Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 46: 207–213. doi:10.1016/j.pnpbp.2012.10.018. ISSN 0278-5846. PMID 23123399.
Ali, Ziad; Roque, Autumn; El-Mallakh, Rif S. (2020-07-01). "A unifying theory for the pathoetiologic mechanism of tardive dyskinesia". Medical Hypotheses. 140: 109682. doi:10.1016/j.mehy.2020.109682. ISSN 0306-9877. PMID 32200182.
Lohr, James B.; Kuczenski, Ronald; Niculescu, Alexander B. (2003-01-01). "Oxidative Mechanisms and Tardive Dyskinesia". CNS Drugs. 17 (1): 47–62. doi:10.2165/00023210-200317010-00004. ISSN 1179-1934. PMID 12467492.
Rana, Abdul Qayyum; Chaudry, Zishan; Blanchet, Pierre (2013). "New and emerging treatments for symptomatic tardive dyskinesia". Drug Design, Development and Therapy. 7: 1329–1340. doi:10.2147/DDDT.S32328. PMC 3825689. PMID 24235816.
Alexander, C; Power, P (2008). "A case of aripiprazole and tardive dyskinesia". Journal of Psychopharmacology. 23 (2): 214–215. doi:10.1177/0269881108089591. PMID 18515468. S2CID 206489666.
Alexander, J (Mar 2013). "Aripiprazole induced tardive dyskinesia-accruing evidence". Aust N Z J Psychiatry. 47 (3): 289–290. doi:10.1177/0004867412461058. PMID 22990431. S2CID 206398532.
Crane, GE (1973). "Is tardive dyskinesia a drug effect?". The American Journal of Psychiatry. 130 (9): 1043–1044. doi:10.1176/ajp.130.9.1043-a. PMID 4727768.
Crane, George E (1973). "Rapid Reversal of Tardive Dyskinesia". American Journal of Psychiatry. 130 (10): 1159. doi:10.1176/ajp.130.10.1159. PMID 4728916.
Yassa, R; Lal, S; Korpassy, A; Ally, J (January 1987). "Nicotine exposure and tardive dyskinesia". Biological Psychiatry. 22 (1): 67–72. doi:10.1016/0006-3223(87)90131-4. PMID 3790642. S2CID 37219161.
Zhang, XY; Yu, YQ; Sun, S; Zhang, X; Li, W; Xiu, MH; Chen da, C; Yang, FD; Zhu, F; Kosten, TA; Kosten, TR (August 2011). "Smoking and tardive dyskinesia in male patients with chronic schizophrenia". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 35 (7): 1765–1769. doi:10.1016/j.pnpbp.2011.06.006. PMID 21723906. S2CID 28294188.
Diehl, A; Reinhard, I; Schmitt, A; Mann, K; Gattaz, WF (January 2009). "Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial". European Psychiatry. 24 (1): 33–40. doi:10.1016/j.eurpsy.2008.07.007. PMID 18774276. S2CID 25228495.
Segman, Ronnen H; Heresco-Levy, Uriel; Finkel, Boris; Inbar, Roi; Neeman, Tal; Schlafman, Michael; Dorevitch, Abe; Yakir, Avraham; Lerner, Arturo; Goltser, Tanya; Shelevoy, Aida; Lerer, Bernard (2000). "Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2C ser and DRD3 gly alleles to susceptibility". Psychopharmacology. 152 (4): 408–413. doi:10.1007/s002130000521. PMID 11140333. S2CID 25105422.
Rauchverger, B; Isakov, V; Jabarin, M (2007). "Olanzapine-Induced Tardive Dystonia Successfully Treated by Tetrabenazine". Journal of Neuropsychiatry. 19 (4): 484–485. doi:10.1176/appi.neuropsych.19.4.484-a. PMID 18070868.
Fernandez, Hubert H; Friedman, Joseph H (2003). "Classification and Treatment of Tardive Syndromes". The Neurologist. 9 (1): 16–27. doi:10.1097/01.nrl.0000038585.58012.97. PMID 12801428. S2CID 22761132.
Lerner, Vladimir (2011). "Antioxidants as a Treatment and Prevention of Tardive Dyskinesia". In Ritsner, Michael S. (ed.). Handbook of Schizophrenia Spectrum Disorders, Volume III. pp. 109–134. doi:10.1007/978-94-007-0834-1_6. ISBN 978-94-007-0833-4.
Soares-Weiser, K; Maayan, N; Bergman, H (17 January 2018). "Vitamin E for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 1 (9): CD000209. doi:10.1002/14651858.CD000209.pub3. PMC 6491331. PMID 29341067.
Lerner, V; Miodownik, C; Kaptsan, A; Cohen, H; Matar, M; Loewenthal, U; Kotler, M (September 2001). "Vitamin B6 in the Treatment of Tardive Dyskinesia: A Double-Blind, Placebo-Controlled, Crossover Study" (PDF). The American Journal of Psychiatry. 158 (9): 1511–1514. doi:10.1176/appi.ajp.158.9.1511. PMID 11532741. Archived from the original (PDF) on 2013-12-03. Retrieved 2013-11-25.
Lerner, V; Miodownik, C; Kaptsan, A; Bersudsky, Y; Libov, I; Sela BA; Witztum, E (November 2007). "Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study". Journal of Clinical Psychiatry. 68 (11): 1648–154. doi:10.4088/jcp.v68n1103. PMID 18052557.
Adelufosi, Adegoke Oloruntoba; Abayomi, Olukayode; Ojo, Tunde Massey-Ferguson (13 April 2015). "Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia". Cochrane Database of Systematic Reviews (4): CD010501. doi:10.1002/14651858.CD010501.pub2. PMC 11064773. PMID 25866243.
Aia, Pratibha G; Revuelta, Gonzalo J; Cloud, Leslie J; Factor, Stewart A (2011). "Tardive Dyskinesia". Current Treatment Options in Neurology. 13 (3): 231–241. doi:10.1007/s11940-011-0117-x. PMID 21365202. S2CID 24308129.
Bergman, H; Bhoopathi, PS; Soares-Weiser, K (20 January 2018). "Benzodiazepines for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 1 (1): CD000205. doi:10.1002/14651858.CD000205.pub3. PMC 6491128. PMID 29352477.
Alabed, S; Latifeh, Y; Mohammad, HA; Bergman, H (17 April 2018). "Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 2018 (4): CD000203. doi:10.1002/14651858.CD000203.pub4. PMC 6513215. PMID 29663328.
Essali, Adib; Soares-Weiser, Karla; Bergman, Hanna; Adams, Clive E (26 March 2018). "Calcium channel blockers for antipsychotic-induced tardive dyskinesia". Cochrane Database of Systematic Reviews. 2018 (3): CD000206. doi:10.1002/14651858.CD000206.pub4. PMC 6494274. PMID 29578611.
Llorca, Pierre-Michel; Chereau, Isabelle; Bayle, Frank-Jean; et al. (2002). "Tardive dyskinesias and antipsychotics: A review". European Psychiatry. 17 (3): 129–138. doi:10.1016/S0924-9338(02)00647-8. PMID 12052573. S2CID 40761404.
Jeste, Dilip V.; Caligiuri, Michael P.; Paulsen, Jane S.; et al. (1995). "Risk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients". Archives of General Psychiatry. 52 (9): 756–765. doi:10.1001/archpsyc.1995.03950210050010. PMID 7654127.
Marshall, DL; Hazlet, TK; Gardner, JS; et al. (2002). "Neuroleptic drug exposure and incidence of tardive dyskinesia: A records-based case-control study". Journal of Managed Care Pharmacy. 8 (4): 259–265. doi:10.18553/jmcp.2002.8.4.259. PMID 14613418.
Tarsy, Daniel; Lungu, Codrin; Baldessarini, Ross J. (2011). "Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs". In Vinken, P. J.; Bruyn, G. W. (eds.). Handbook of Clinical Neurology. Hyperkinetic Movement Disorders. Vol. 100. pp. 601–616. doi:10.1016/B978-0-444-52014-2.00043-4. ISBN 978-0-444-52014-2. PMID 21496610.
Jeste, Dilip V.; Caligiuri, Michael P. (1993). "Tardive Dyskinesia". Schizophrenia Bulletin. 19 (2): 303–315. doi:10.1093/schbul/19.2.303. PMID 8100643.

dukehealth.org

Duke University Health System. (2010, May 17). Additional movement disorders. Retrieved from "Treatments for Adults | Duke Health". Archived from the original on 2012-05-24. Retrieved 2012-05-01.

fda.gov

Commissioner, Office of the. "Press Announcements - FDA approves first drug to treat tardive dyskinesia". www.fda.gov. Archived from the original on 12 April 2017. Retrieved 12 April 2017.

accessdata.fda.gov

"Drug Approval Package: Austedo (deutetrabenazine) Tablets". www.accessdata.fda.gov. Retrieved 2018-09-14.

medscape.com

emedicine.medscape.com

"Tardive Dyskinesia". Medscape Reference. WebMD. 9 February 2012. Archived from the original on 3 December 2013. Retrieved 25 November 2013.

nami.org

Nasrallah, H. (2003, Sept). Tardive dyskinesia. Retrieved from "NAMI | Tardive Dyskinesia". Archived from the original on 2012-04-21. Retrieved 2012-05-01.

nih.gov

pubmed.ncbi.nlm.nih.gov

Vijayakumar, D; Jankovic, J (May 2016). "Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia". Drugs. 76 (7): 779–787. doi:10.1007/s40265-016-0568-1. PMID 27091214. S2CID 13570794.
Carbon, M; Hsieh, CH; Kane, JM; Correll, CU (March 2017). "Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis". The Journal of Clinical Psychiatry. 78 (3): e264 – e278. doi:10.4088/jcp.16r10832. PMID 28146614. S2CID 3773500.
Gerlach, J.; Casey, D.E. (1988). "Tardive dyskinesia". Acta Psychiatrica Scandinavica. 77 (4): 369–378. doi:10.1111/j.1600-0447.1988.tb05138.x. ISSN 0001-690X. PMID 2898870.
Waln, Olga; Jankovic, Joseph (2013). "An Update on Tardive Dyskinesia: From Phenomenology to Treatment". Tremor and Other Hyperkinetic Movements. 3. doi:10.7916/D88P5Z71 (inactive 2024-11-01). PMC 3709416. PMID 23858394.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Waln, Olga; Jankovic, Joseph (2013-07-12). "An Update on Tardive Dyskinesia: From Phenomenology to Treatment". Tremor and Other Hyperkinetic Movements. 3: tre–03–161-4138-1. doi:10.7916/D88P5Z71 (inactive 2024-11-01). ISSN 2160-8288. PMC 3709416. PMID 23858394.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Yassa, R.; Lal, S. (1986). "Respiratory irregularity and tardive dyskinesia a prevalence study". Acta Psychiatrica Scandinavica. 73 (5): 506–510. doi:10.1111/j.1600-0447.1986.tb02717.x. PMID 2875609. S2CID 25313407.
Yassa, Ramzy; Jones, Barry D. (1985). "Complications of tardive dyskinesia: A review". Psychosomatics. 26 (4): 305–307, 310, 312–313. doi:10.1016/S0033-3182(85)72863-0. PMID 2859630.
Dean, C. E.; Thuras, P. D. (2009). "Mortality and tardive dyskinesia: Long-term study using the US National Death Index". The British Journal of Psychiatry. 194 (4): 360–364. doi:10.1192/bjp.bp.108.049395. PMID 19336789.
Baldessarini, Ross J. (1988). "A summary of current knowledge of tardive dyskinesia". L'Encéphale. 14 (Spec Issue): 263–8. PMID 2905654.
Cho, Chul-Hyun; Lee, Heon-Jeong (2013-10-01). "Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 46: 207–213. doi:10.1016/j.pnpbp.2012.10.018. ISSN 0278-5846. PMID 23123399.
Ali, Ziad; Roque, Autumn; El-Mallakh, Rif S. (2020-07-01). "A unifying theory for the pathoetiologic mechanism of tardive dyskinesia". Medical Hypotheses. 140: 109682. doi:10.1016/j.mehy.2020.109682. ISSN 0306-9877. PMID 32200182.
Lohr, James B.; Kuczenski, Ronald; Niculescu, Alexander B. (2003-01-01). "Oxidative Mechanisms and Tardive Dyskinesia". CNS Drugs. 17 (1): 47–62. doi:10.2165/00023210-200317010-00004. ISSN 1179-1934. PMID 12467492.
Rana, Abdul Qayyum; Chaudry, Zishan; Blanchet, Pierre (2013). "New and emerging treatments for symptomatic tardive dyskinesia". Drug Design, Development and Therapy. 7: 1329–1340. doi:10.2147/DDDT.S32328. PMC 3825689. PMID 24235816.
Alexander, C; Power, P (2008). "A case of aripiprazole and tardive dyskinesia". Journal of Psychopharmacology. 23 (2): 214–215. doi:10.1177/0269881108089591. PMID 18515468. S2CID 206489666.
Alexander, J (Mar 2013). "Aripiprazole induced tardive dyskinesia-accruing evidence". Aust N Z J Psychiatry. 47 (3): 289–290. doi:10.1177/0004867412461058. PMID 22990431. S2CID 206398532.
Crane, GE (1973). "Is tardive dyskinesia a drug effect?". The American Journal of Psychiatry. 130 (9): 1043–1044. doi:10.1176/ajp.130.9.1043-a. PMID 4727768.
Crane, George E (1973). "Rapid Reversal of Tardive Dyskinesia". American Journal of Psychiatry. 130 (10): 1159. doi:10.1176/ajp.130.10.1159. PMID 4728916.
Yassa, R; Lal, S; Korpassy, A; Ally, J (January 1987). "Nicotine exposure and tardive dyskinesia". Biological Psychiatry. 22 (1): 67–72. doi:10.1016/0006-3223(87)90131-4. PMID 3790642. S2CID 37219161.
Chong, SA; Tan, EC; Tan, CH; Mythily (May 2003). "Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene". J Psychiatry Neurosci. 28 (3): 185–189. PMC 161742. PMID 12790158.
Zhang, XY; Yu, YQ; Sun, S; Zhang, X; Li, W; Xiu, MH; Chen da, C; Yang, FD; Zhu, F; Kosten, TA; Kosten, TR (August 2011). "Smoking and tardive dyskinesia in male patients with chronic schizophrenia". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 35 (7): 1765–1769. doi:10.1016/j.pnpbp.2011.06.006. PMID 21723906. S2CID 28294188.
Diehl, A; Reinhard, I; Schmitt, A; Mann, K; Gattaz, WF (January 2009). "Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial". European Psychiatry. 24 (1): 33–40. doi:10.1016/j.eurpsy.2008.07.007. PMID 18774276. S2CID 25228495.
Segman, Ronnen H; Heresco-Levy, Uriel; Finkel, Boris; Inbar, Roi; Neeman, Tal; Schlafman, Michael; Dorevitch, Abe; Yakir, Avraham; Lerner, Arturo; Goltser, Tanya; Shelevoy, Aida; Lerer, Bernard (2000). "Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2C ser and DRD3 gly alleles to susceptibility". Psychopharmacology. 152 (4): 408–413. doi:10.1007/s002130000521. PMID 11140333. S2CID 25105422.
Rauchverger, B; Isakov, V; Jabarin, M (2007). "Olanzapine-Induced Tardive Dystonia Successfully Treated by Tetrabenazine". Journal of Neuropsychiatry. 19 (4): 484–485. doi:10.1176/appi.neuropsych.19.4.484-a. PMID 18070868.
Fernandez, Hubert H; Friedman, Joseph H (2003). "Classification and Treatment of Tardive Syndromes". The Neurologist. 9 (1): 16–27. doi:10.1097/01.nrl.0000038585.58012.97. PMID 12801428. S2CID 22761132.
Saltz, Bruce L.; Robinson, Delbert G.; Woerner, Margaret G. (2004). "Recognizing and Managing Antipsychotic Drug Treatment Side Effects in the Elderly". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (Suppl 2): 14–19. PMC 487007. PMID 16001096.
Soares-Weiser, K; Maayan, N; Bergman, H (17 January 2018). "Vitamin E for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 1 (9): CD000209. doi:10.1002/14651858.CD000209.pub3. PMC 6491331. PMID 29341067.
Lerner, V; Miodownik, C; Kaptsan, A; Cohen, H; Matar, M; Loewenthal, U; Kotler, M (September 2001). "Vitamin B6 in the Treatment of Tardive Dyskinesia: A Double-Blind, Placebo-Controlled, Crossover Study" (PDF). The American Journal of Psychiatry. 158 (9): 1511–1514. doi:10.1176/appi.ajp.158.9.1511. PMID 11532741. Archived from the original (PDF) on 2013-12-03. Retrieved 2013-11-25.
Lerner, V; Miodownik, C; Kaptsan, A; Bersudsky, Y; Libov, I; Sela BA; Witztum, E (November 2007). "Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study". Journal of Clinical Psychiatry. 68 (11): 1648–154. doi:10.4088/jcp.v68n1103. PMID 18052557.
Adelufosi, Adegoke Oloruntoba; Abayomi, Olukayode; Ojo, Tunde Massey-Ferguson (13 April 2015). "Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia". Cochrane Database of Systematic Reviews (4): CD010501. doi:10.1002/14651858.CD010501.pub2. PMC 11064773. PMID 25866243.
Aia, Pratibha G; Revuelta, Gonzalo J; Cloud, Leslie J; Factor, Stewart A (2011). "Tardive Dyskinesia". Current Treatment Options in Neurology. 13 (3): 231–241. doi:10.1007/s11940-011-0117-x. PMID 21365202. S2CID 24308129.
Bergman, H; Bhoopathi, PS; Soares-Weiser, K (20 January 2018). "Benzodiazepines for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 1 (1): CD000205. doi:10.1002/14651858.CD000205.pub3. PMC 6491128. PMID 29352477.
Alabed, S; Latifeh, Y; Mohammad, HA; Bergman, H (17 April 2018). "Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 2018 (4): CD000203. doi:10.1002/14651858.CD000203.pub4. PMC 6513215. PMID 29663328.
Essali, Adib; Soares-Weiser, Karla; Bergman, Hanna; Adams, Clive E (26 March 2018). "Calcium channel blockers for antipsychotic-induced tardive dyskinesia". Cochrane Database of Systematic Reviews. 2018 (3): CD000206. doi:10.1002/14651858.CD000206.pub4. PMC 6494274. PMID 29578611.
Llorca, Pierre-Michel; Chereau, Isabelle; Bayle, Frank-Jean; et al. (2002). "Tardive dyskinesias and antipsychotics: A review". European Psychiatry. 17 (3): 129–138. doi:10.1016/S0924-9338(02)00647-8. PMID 12052573. S2CID 40761404.
Glenmullen, Joseph (2001). Prozac Backlash: Overcoming the Dangers of Prozac, Zoloft, Paxil, and Other Antidepressants With Safe, Effective Alternatives. New York: Simon & Schuster. p. 38. ISBN 978-0-7432-0062-2.^{[unreliable medical source?]} ::referring to Glazer, William M.; Morgenstern, Hal; Doucette, John T. (1993). "Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications". Journal of Clinical Psychiatry. 54 (4): 133–139. PMID 8098030.
Jeste, Dilip V.; Caligiuri, Michael P.; Paulsen, Jane S.; et al. (1995). "Risk of Tardive Dyskinesia in Older Patients: A Prospective Longitudinal Study of 266 Outpatients". Archives of General Psychiatry. 52 (9): 756–765. doi:10.1001/archpsyc.1995.03950210050010. PMID 7654127.
Marshall, DL; Hazlet, TK; Gardner, JS; et al. (2002). "Neuroleptic drug exposure and incidence of tardive dyskinesia: A records-based case-control study". Journal of Managed Care Pharmacy. 8 (4): 259–265. doi:10.18553/jmcp.2002.8.4.259. PMID 14613418.
Tarsy, Daniel; Lungu, Codrin; Baldessarini, Ross J. (2011). "Epidemiology of tardive dyskinesia before and during the era of modern antipsychotic drugs". In Vinken, P. J.; Bruyn, G. W. (eds.). Handbook of Clinical Neurology. Hyperkinetic Movement Disorders. Vol. 100. pp. 601–616. doi:10.1016/B978-0-444-52014-2.00043-4. ISBN 978-0-444-52014-2. PMID 21496610.
Jeste, Dilip V.; Caligiuri, Michael P. (1993). "Tardive Dyskinesia". Schizophrenia Bulletin. 19 (2): 303–315. doi:10.1093/schbul/19.2.303. PMID 8100643.

ncbi.nlm.nih.gov

Waln, Olga; Jankovic, Joseph (2013). "An Update on Tardive Dyskinesia: From Phenomenology to Treatment". Tremor and Other Hyperkinetic Movements. 3. doi:10.7916/D88P5Z71 (inactive 2024-11-01). PMC 3709416. PMID 23858394.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Waln, Olga; Jankovic, Joseph (2013-07-12). "An Update on Tardive Dyskinesia: From Phenomenology to Treatment". Tremor and Other Hyperkinetic Movements. 3: tre–03–161-4138-1. doi:10.7916/D88P5Z71 (inactive 2024-11-01). ISSN 2160-8288. PMC 3709416. PMID 23858394.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Rana, Abdul Qayyum; Chaudry, Zishan; Blanchet, Pierre (2013). "New and emerging treatments for symptomatic tardive dyskinesia". Drug Design, Development and Therapy. 7: 1329–1340. doi:10.2147/DDDT.S32328. PMC 3825689. PMID 24235816.
Chong, SA; Tan, EC; Tan, CH; Mythily (May 2003). "Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene". J Psychiatry Neurosci. 28 (3): 185–189. PMC 161742. PMID 12790158.
Saltz, Bruce L.; Robinson, Delbert G.; Woerner, Margaret G. (2004). "Recognizing and Managing Antipsychotic Drug Treatment Side Effects in the Elderly". Primary Care Companion to the Journal of Clinical Psychiatry. 6 (Suppl 2): 14–19. PMC 487007. PMID 16001096.
Soares-Weiser, K; Maayan, N; Bergman, H (17 January 2018). "Vitamin E for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 1 (9): CD000209. doi:10.1002/14651858.CD000209.pub3. PMC 6491331. PMID 29341067.
Adelufosi, Adegoke Oloruntoba; Abayomi, Olukayode; Ojo, Tunde Massey-Ferguson (13 April 2015). "Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesia". Cochrane Database of Systematic Reviews (4): CD010501. doi:10.1002/14651858.CD010501.pub2. PMC 11064773. PMID 25866243.
Bergman, H; Bhoopathi, PS; Soares-Weiser, K (20 January 2018). "Benzodiazepines for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 1 (1): CD000205. doi:10.1002/14651858.CD000205.pub3. PMC 6491128. PMID 29352477.
Alabed, S; Latifeh, Y; Mohammad, HA; Bergman, H (17 April 2018). "Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia". The Cochrane Database of Systematic Reviews. 2018 (4): CD000203. doi:10.1002/14651858.CD000203.pub4. PMC 6513215. PMID 29663328.
Essali, Adib; Soares-Weiser, Karla; Bergman, Hanna; Adams, Clive E (26 March 2018). "Calcium channel blockers for antipsychotic-induced tardive dyskinesia". Cochrane Database of Systematic Reviews. 2018 (3): CD000206. doi:10.1002/14651858.CD000206.pub4. PMC 6494274. PMID 29578611.

ninds.nih.gov

"Tardive Dyskinesia Information Page". National Institute of Neurological Disorders and Stroke. Archived from the original on 2017-07-04.
National Institutes of Health, National Institute of Neurological Disorders and Stroke. (2011). Ninds tardive dyskinesia information page. Retrieved from website: "Tardive Dyskinesia Information Page: National Institute of Neurological Disorders and Stroke (NINDS)". Archived from the original on 2012-04-27. Retrieved 2012-05-01.

rarediseases.info.nih.gov

"Tardive dyskinesia". rarediseases.info.nih.gov. 1 June 2017. Archived from the original on 18 June 2017. Retrieved 10 June 2017.

priory.com

Hoerger, Michael. "The primacy of neuroleptic-Induced D2 receptor hypersensitivity in tardive dyskinesia". Archived from the original on 2008-01-18.^{[unreliable medical source?]}

psychiatryonline.org

ajp.psychiatryonline.org

Lerner, V; Miodownik, C; Kaptsan, A; Cohen, H; Matar, M; Loewenthal, U; Kotler, M (September 2001). "Vitamin B6 in the Treatment of Tardive Dyskinesia: A Double-Blind, Placebo-Controlled, Crossover Study" (PDF). The American Journal of Psychiatry. 158 (9): 1511–1514. doi:10.1176/appi.ajp.158.9.1511. PMID 11532741. Archived from the original (PDF) on 2013-12-03. Retrieved 2013-11-25.

rarediseases.org

"Tardive Dyskinesia". NORD (National Organization for Rare Disorders). 2015. Archived from the original on 28 August 2017. Retrieved 11 June 2017.

sciencedirect.com

Cho, Chul-Hyun; Lee, Heon-Jeong (2013-10-01). "Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 46: 207–213. doi:10.1016/j.pnpbp.2012.10.018. ISSN 0278-5846. PMID 23123399.
Ali, Ziad; Roque, Autumn; El-Mallakh, Rif S. (2020-07-01). "A unifying theory for the pathoetiologic mechanism of tardive dyskinesia". Medical Hypotheses. 140: 109682. doi:10.1016/j.mehy.2020.109682. ISSN 0306-9877. PMID 32200182.

semanticscholar.org

api.semanticscholar.org

Vijayakumar, D; Jankovic, J (May 2016). "Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia". Drugs. 76 (7): 779–787. doi:10.1007/s40265-016-0568-1. PMID 27091214. S2CID 13570794.
Carbon, M; Hsieh, CH; Kane, JM; Correll, CU (March 2017). "Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis". The Journal of Clinical Psychiatry. 78 (3): e264 – e278. doi:10.4088/jcp.16r10832. PMID 28146614. S2CID 3773500.
Yassa, R.; Lal, S. (1986). "Respiratory irregularity and tardive dyskinesia a prevalence study". Acta Psychiatrica Scandinavica. 73 (5): 506–510. doi:10.1111/j.1600-0447.1986.tb02717.x. PMID 2875609. S2CID 25313407.
Alexander, C; Power, P (2008). "A case of aripiprazole and tardive dyskinesia". Journal of Psychopharmacology. 23 (2): 214–215. doi:10.1177/0269881108089591. PMID 18515468. S2CID 206489666.
Alexander, J (Mar 2013). "Aripiprazole induced tardive dyskinesia-accruing evidence". Aust N Z J Psychiatry. 47 (3): 289–290. doi:10.1177/0004867412461058. PMID 22990431. S2CID 206398532.
Yassa, R; Lal, S; Korpassy, A; Ally, J (January 1987). "Nicotine exposure and tardive dyskinesia". Biological Psychiatry. 22 (1): 67–72. doi:10.1016/0006-3223(87)90131-4. PMID 3790642. S2CID 37219161.
Zhang, XY; Yu, YQ; Sun, S; Zhang, X; Li, W; Xiu, MH; Chen da, C; Yang, FD; Zhu, F; Kosten, TA; Kosten, TR (August 2011). "Smoking and tardive dyskinesia in male patients with chronic schizophrenia". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 35 (7): 1765–1769. doi:10.1016/j.pnpbp.2011.06.006. PMID 21723906. S2CID 28294188.
Diehl, A; Reinhard, I; Schmitt, A; Mann, K; Gattaz, WF (January 2009). "Does the degree of smoking effect the severity of tardive dyskinesia? A longitudinal clinical trial". European Psychiatry. 24 (1): 33–40. doi:10.1016/j.eurpsy.2008.07.007. PMID 18774276. S2CID 25228495.
Segman, Ronnen H; Heresco-Levy, Uriel; Finkel, Boris; Inbar, Roi; Neeman, Tal; Schlafman, Michael; Dorevitch, Abe; Yakir, Avraham; Lerner, Arturo; Goltser, Tanya; Shelevoy, Aida; Lerer, Bernard (2000). "Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: Additive contribution of 5-HT2C ser and DRD3 gly alleles to susceptibility". Psychopharmacology. 152 (4): 408–413. doi:10.1007/s002130000521. PMID 11140333. S2CID 25105422.
Fernandez, Hubert H; Friedman, Joseph H (2003). "Classification and Treatment of Tardive Syndromes". The Neurologist. 9 (1): 16–27. doi:10.1097/01.nrl.0000038585.58012.97. PMID 12801428. S2CID 22761132.
Aia, Pratibha G; Revuelta, Gonzalo J; Cloud, Leslie J; Factor, Stewart A (2011). "Tardive Dyskinesia". Current Treatment Options in Neurology. 13 (3): 231–241. doi:10.1007/s11940-011-0117-x. PMID 21365202. S2CID 24308129.
Llorca, Pierre-Michel; Chereau, Isabelle; Bayle, Frank-Jean; et al. (2002). "Tardive dyskinesias and antipsychotics: A review". European Psychiatry. 17 (3): 129–138. doi:10.1016/S0924-9338(02)00647-8. PMID 12052573. S2CID 40761404.

springer.com

link.springer.com

Lohr, James B.; Kuczenski, Ronald; Niculescu, Alexander B. (2003-01-01). "Oxidative Mechanisms and Tardive Dyskinesia". CNS Drugs. 17 (1): 47–62. doi:10.2165/00023210-200317010-00004. ISSN 1179-1934. PMID 12467492.

web.archive.org

"Tardive dyskinesia". rarediseases.info.nih.gov. 1 June 2017. Archived from the original on 18 June 2017. Retrieved 10 June 2017.
"Tardive Dyskinesia". NORD (National Organization for Rare Disorders). 2015. Archived from the original on 28 August 2017. Retrieved 11 June 2017.
"Tardive Dyskinesia Information Page". National Institute of Neurological Disorders and Stroke. Archived from the original on 2017-07-04.
"Tardive Dyskinesia". Medscape Reference. WebMD. 9 February 2012. Archived from the original on 3 December 2013. Retrieved 25 November 2013.
National Institutes of Health, National Institute of Neurological Disorders and Stroke. (2011). Ninds tardive dyskinesia information page. Retrieved from website: "Tardive Dyskinesia Information Page: National Institute of Neurological Disorders and Stroke (NINDS)". Archived from the original on 2012-04-27. Retrieved 2012-05-01.
Nasrallah, H. (2003, Sept). Tardive dyskinesia. Retrieved from "NAMI | Tardive Dyskinesia". Archived from the original on 2012-04-21. Retrieved 2012-05-01.
Duke University Health System. (2010, May 17). Additional movement disorders. Retrieved from "Treatments for Adults | Duke Health". Archived from the original on 2012-05-24. Retrieved 2012-05-01.
Hoerger, Michael. "The primacy of neuroleptic-Induced D2 receptor hypersensitivity in tardive dyskinesia". Archived from the original on 2008-01-18.^{[unreliable medical source?]}
Commissioner, Office of the. "Press Announcements - FDA approves first drug to treat tardive dyskinesia". www.fda.gov. Archived from the original on 12 April 2017. Retrieved 12 April 2017.
Lerner, V; Miodownik, C; Kaptsan, A; Cohen, H; Matar, M; Loewenthal, U; Kotler, M (September 2001). "Vitamin B6 in the Treatment of Tardive Dyskinesia: A Double-Blind, Placebo-Controlled, Crossover Study" (PDF). The American Journal of Psychiatry. 158 (9): 1511–1514. doi:10.1176/appi.ajp.158.9.1511. PMID 11532741. Archived from the original (PDF) on 2013-12-03. Retrieved 2013-11-25.

wiley.com

onlinelibrary.wiley.com

Gerlach, J.; Casey, D.E. (1988). "Tardive dyskinesia". Acta Psychiatrica Scandinavica. 77 (4): 369–378. doi:10.1111/j.1600-0447.1988.tb05138.x. ISSN 0001-690X. PMID 2898870.

worldcat.org

search.worldcat.org

Gerlach, J.; Casey, D.E. (1988). "Tardive dyskinesia". Acta Psychiatrica Scandinavica. 77 (4): 369–378. doi:10.1111/j.1600-0447.1988.tb05138.x. ISSN 0001-690X. PMID 2898870.
Waln, Olga; Jankovic, Joseph (2013-07-12). "An Update on Tardive Dyskinesia: From Phenomenology to Treatment". Tremor and Other Hyperkinetic Movements. 3: tre–03–161-4138-1. doi:10.7916/D88P5Z71 (inactive 2024-11-01). ISSN 2160-8288. PMC 3709416. PMID 23858394.{{cite journal}}: CS1 maint: DOI inactive as of November 2024 (link)
Cho, Chul-Hyun; Lee, Heon-Jeong (2013-10-01). "Oxidative stress and tardive dyskinesia: Pharmacogenetic evidence". Progress in Neuro-Psychopharmacology and Biological Psychiatry. 46: 207–213. doi:10.1016/j.pnpbp.2012.10.018. ISSN 0278-5846. PMID 23123399.
Ali, Ziad; Roque, Autumn; El-Mallakh, Rif S. (2020-07-01). "A unifying theory for the pathoetiologic mechanism of tardive dyskinesia". Medical Hypotheses. 140: 109682. doi:10.1016/j.mehy.2020.109682. ISSN 0306-9877. PMID 32200182.
Lohr, James B.; Kuczenski, Ronald; Niculescu, Alexander B. (2003-01-01). "Oxidative Mechanisms and Tardive Dyskinesia". CNS Drugs. 17 (1): 47–62. doi:10.2165/00023210-200317010-00004. ISSN 1179-1934. PMID 12467492.